Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
Launched by ABBVIE · Jan 24, 2018
Trial Information
Current as of May 23, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a medication called venetoclax works for people with Chronic Lymphocytic Leukemia (CLL) in real-life situations. The goal is to understand how effective this treatment is and how it is managed by healthcare providers when patients start using it. The trial is currently active but not recruiting new participants.
To be eligible for this study, participants must have a confirmed diagnosis of CLL and be approved by their doctor to start treatment with venetoclax. It’s important that these patients can be followed closely by their doctor throughout the study. Additionally, participants must agree to the use of their data for the study. However, individuals who have participated in another clinical trial involving an experimental drug for CLL in the last 30 days are not eligible. Those who join can expect to share their treatment experiences, which will help researchers gather valuable information on the effectiveness of venetoclax in treating CLL.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
- • Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
- • Participants the physician believes he can personally follow over all the study period.
- • Participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control.
- Exclusion Criteria:
- • - Participating in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cannes Cedex, Alpes Maritimes, France
Carcassonne, Aude, France
Clermont, Auvergne Rhone Alpes, France
Clermont Ferrand, Auvergne, France
Vesoul Cedex, Bourgogne Franche Comte, France
Rennes Cedex 9, Bretagne, France
Vannes Cedex, Bretagne, France
Orleans Cedex 2, Centre Val De Loire, France
Besancon, Doubs, France
Limoges Cedex 1, Franche Comte, France
Bordeaux, Gironde, France
Pringy Cedex, Haute Savoie, France
Montpellier Cedex 5, Herault, France
Bobigny, Ile De France, France
Saint Malo, Ille Et Vilaine, France
Tours Cedex 9, Indre Et Loire, France
Saint Pierre, La Reunion, France
Vandœuvre Lès Nancy, Meurthe Et Moselle, France
Poitiers, Poitou Charentes, France
Bayonne, Pyrenees Atlantiques, France
Lyon Cedex 08, Rhone, France
Le Mans Cedex 9, Sarthe, France
Melun Cedex, Seine Et Marne, France
Amiens Cedex 1, Somme, France
Pontoise, Val D Oise, France
Pontoise, Val D Oise, France
Villejuif Cedex, Val De Marne, France
Agen Cedex 9, , France
Aix En Provence Cedex 1, , France
Argenteuil, , France
Blois, , France
Bourg En Bresse, , France
Brest, , France
Caen, , France
Cesson Sevigne, , France
Challes Les Eaux, , France
Chalon Sur Saone, , France
Cholet, , France
Clamart, , France
Creil, , France
Desertines, , France
La Tronche, , France
Le Chesnay, , France
Le Kremlin Bicetre, , France
Le Mans, , France
Libourne, , France
Lille Cedex, , France
Lyon, , France
Marseille, , France
Monaco, , France
Mont De Marsan, , France
Mulhouse, , France
Narbonne, , France
Nimes Cedex 09, , France
Nimes Cedex 09, , France
Paris, , France
Paris, , France
Perigueux, , France
Perpignan, , France
Quimper, , France
Reims Cedex, , France
Roubaix Cedex 1, , France
Rouen, , France
Saint Brieuc, , France
St Germain En Laye Cedex, , France
Strasbourg Cedex, , France
Thionville, , France
Toulouse Cedex 9, , France
Trevenans, , France
Roubaix Cedex 1, Hauts De France, France
Orleans Cedex 2, Loiret, France
Reims Cedex, Marne, France
Vandoeuvre Les Nancy, Meurthe Et Moselle, France
Bayonne, Pyrenees Atlantiques, France
St Germain En Laye, Yvelines, France
Epagny Metz Tessy, , France
Marseille, Bouches Du Rhone, France
Quimper, Finistere, France
Montpellier Cedex 5, Herault, France
La Tronche, Isere, France
Vannes Cedex, Morbihan, France
Poitiers, Vienne, France
Orléans, , France
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials